A Phase II Study of Neratinib in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Researcher
Cynthia Ma, MD, PhD, Washington University, St. Louis, MO
Study review

The purpose of this study was to see whether neratinib is effective in treating HER2-negative metastatic tumors that have this specific HER2 mutation.

The initial Call to Action for this study was on 3/19/2014 and the researchers closed enrollment on 3/24/2020. The Love Research Army provided them with 74 participants who were interested in enrolling in the study.

Resulting Publications: